From adenoma to CRC stages: the oral-gut microbiome axis as a source of potential microbial and metabolic biomarkers of malignancy.
Microbiota
biomarkers
cancer staging
colonic adenomatous polyps
colorectal cancer
metabolomics
microbiota
Journal
Neoplasia (New York, N.Y.)
ISSN: 1476-5586
Titre abrégé: Neoplasia
Pays: United States
ID NLM: 100886622
Informations de publication
Date de publication:
06 2023
06 2023
Historique:
received:
10
11
2022
revised:
30
03
2023
accepted:
05
04
2023
medline:
25
4
2023
pubmed:
15
4
2023
entrez:
14
4
2023
Statut:
ppublish
Résumé
Approximately 95% of Colorectal cancers (CRC) consist of adenocarcinomas originating from colonic Adenomatous polyps (AP). Increasing importance in CRC occurrence and progression has been attributed to the gut microbiota; however, a huge proportion of microorganisms inhabit the human digestive system. So, to comprehensively study the microbial spatial variations and their role in CRC progression, from AP to the different CRC phases, a holistic vision is imperative, including the simultaneous evaluation of multiple niches from the gastrointestinal system. Through an integrated approach, we identified potential microbial and metabolic biomarkers, able to discriminate human CRC from AP and/or also the different Tumor node metastasis (TNM) staging. In addition, as the microbiota contributes to the production of essential metabolic products detectable in fecal samples, we analysed and compared metabolites obtained from CRC and AP patients by using a Nuclear magnetic resonance (NMR) approach. In this observational study, saliva, tissue and stool samples from 61 patients, have been collected, including 46 CRC and 15 AP patients, age and sex-matched, undergoing surgery in 2018 at the Careggi University Hospital (Florence, Italy). First, the microbiota in the three-district between CRC and AP patients has been characterized, as well as in different CRC TNM stages. Subsequently, proton NMR spectroscopy has been used in combination with multivariate and univariate statistical approaches, to define the fecal metabolic profile of a restricted group of CRC and AP patients. CRC patients display a different profile of tissue and fecal microbiota with respect to AP patients. Significant differences have been observed in CRC tissue microbial clades, with a rise of the Fusobacterium genus. In addition, significant taxa increase at the genus level has been observed in stool samples of CRC patients. Furthermore, Fusobacterium found in intestinal tissue has been positively correlated with fecal Parvimonas, for the first time. Moreover, as predicted by metagenomics pathway analysis, a significant increase of lactate (p=0.037) has been observed in the CRC fecal metabolic profiles, and positively correlated with Bifidobacterium (p=0.036). Finally, minor bacterial differences in CRC patients at stage T2 (TNM classification) have been detected, with a raise of the Spirochaetota phylum in CRC samples, with a slight increase of the Alphaproteobacteria class in fecal samples. Our results suggest the importance of microbiota communities and oncometabolites in CRC development. Further studies on CRC/AP management with a focus on CRC assessment are needed to investigate novel microbial-related diagnostic tools aimed to improve therapeutic interventions.
Sections du résumé
BACKGROUND
Approximately 95% of Colorectal cancers (CRC) consist of adenocarcinomas originating from colonic Adenomatous polyps (AP). Increasing importance in CRC occurrence and progression has been attributed to the gut microbiota; however, a huge proportion of microorganisms inhabit the human digestive system. So, to comprehensively study the microbial spatial variations and their role in CRC progression, from AP to the different CRC phases, a holistic vision is imperative, including the simultaneous evaluation of multiple niches from the gastrointestinal system. Through an integrated approach, we identified potential microbial and metabolic biomarkers, able to discriminate human CRC from AP and/or also the different Tumor node metastasis (TNM) staging. In addition, as the microbiota contributes to the production of essential metabolic products detectable in fecal samples, we analysed and compared metabolites obtained from CRC and AP patients by using a Nuclear magnetic resonance (NMR) approach.
METHODS
In this observational study, saliva, tissue and stool samples from 61 patients, have been collected, including 46 CRC and 15 AP patients, age and sex-matched, undergoing surgery in 2018 at the Careggi University Hospital (Florence, Italy). First, the microbiota in the three-district between CRC and AP patients has been characterized, as well as in different CRC TNM stages. Subsequently, proton NMR spectroscopy has been used in combination with multivariate and univariate statistical approaches, to define the fecal metabolic profile of a restricted group of CRC and AP patients.
RESULTS
CRC patients display a different profile of tissue and fecal microbiota with respect to AP patients. Significant differences have been observed in CRC tissue microbial clades, with a rise of the Fusobacterium genus. In addition, significant taxa increase at the genus level has been observed in stool samples of CRC patients. Furthermore, Fusobacterium found in intestinal tissue has been positively correlated with fecal Parvimonas, for the first time. Moreover, as predicted by metagenomics pathway analysis, a significant increase of lactate (p=0.037) has been observed in the CRC fecal metabolic profiles, and positively correlated with Bifidobacterium (p=0.036). Finally, minor bacterial differences in CRC patients at stage T2 (TNM classification) have been detected, with a raise of the Spirochaetota phylum in CRC samples, with a slight increase of the Alphaproteobacteria class in fecal samples.
CONCLUSION
Our results suggest the importance of microbiota communities and oncometabolites in CRC development. Further studies on CRC/AP management with a focus on CRC assessment are needed to investigate novel microbial-related diagnostic tools aimed to improve therapeutic interventions.
Identifiants
pubmed: 37058886
pii: S1476-5586(23)00026-X
doi: 10.1016/j.neo.2023.100901
pmc: PMC10130693
pii:
doi:
Substances chimiques
Biomarkers
0
Types de publication
Observational Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
100901Informations de copyright
Copyright © 2023. Published by Elsevier Inc.
Déclaration de conflit d'intérêts
Declaration of Competing Interest No conflict of interest.
Références
Anal Chem. 2006 Jul 1;78(13):4281-90
pubmed: 16808434
Sci Rep. 2018 Jul 9;8(1):10329
pubmed: 29985435
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
Sci Rep. 2021 Feb 3;11(1):2925
pubmed: 33536501
World J Gastroenterol. 2021 Oct 14;27(38):6430-6441
pubmed: 34720532
Int J Cancer. 2020 Jun 15;146(12):3256-3266
pubmed: 31495913
Cancers (Basel). 2020 May 02;12(5):
pubmed: 32370168
Gut. 2017 Apr;66(4):633-643
pubmed: 26992426
Breast Cancer Res Treat. 2020 Jul;182(2):451-463
pubmed: 32468338
Sci Rep. 2020 Sep 17;10(1):15250
pubmed: 32943695
Environ Microbiol. 2020 Nov;22(11):4863-4875
pubmed: 33001550
Anal Chem. 2015 Jun 16;87(12):5930-7
pubmed: 25985090
Am J Clin Nutr. 2015 Jan;101(1):192-201
pubmed: 25527763
J Gastroenterol Hepatol. 2002 Aug;17(8):849-53
pubmed: 12164960
Theranostics. 2019 May 31;9(14):4101-4114
pubmed: 31281534
Cancers (Basel). 2023 Mar 04;15(5):
pubmed: 36900392
Sci Rep. 2020 Dec 3;10(1):21057
pubmed: 33273632
J Crohns Colitis. 2021 Sep 25;15(9):1500-1516
pubmed: 33611347
Gut. 2012 Jun;61(6):794-7
pubmed: 22490520
Annu Rev Immunol. 2012;30:677-706
pubmed: 22224761
Lancet Oncol. 2019 Feb;20(2):e77-e91
pubmed: 30712808
Metabolites. 2019 Mar 22;9(3):
pubmed: 30909447
Front Immunol. 2022 Aug 26;13:876195
pubmed: 36091047
Cancer Immunol Immunother. 2022 Oct;71(10):2565-2575
pubmed: 35301576
J Nutr. 1998 Jan;128(1):91-6
pubmed: 9430608
Gut Microbes. 2020 Sep 2;11(5):1300-1313
pubmed: 32329665
Microbiome. 2014 Jun 17;2:20
pubmed: 24967088
Clin Med Res. 2007 Dec;5(4):228-37
pubmed: 18086907
Oncologist. 2004;9 Suppl 5:4-9
pubmed: 15591417
Cancers (Basel). 2022 Jan 30;14(3):
pubmed: 35158992
Cancer Biomark. 2010;9(1-6):235-65
pubmed: 22112479
Cell Microbiol. 2014 Feb;16(2):179-84
pubmed: 24286560
Asia Pac J Clin Oncol. 2021 Aug;17(4):403-413
pubmed: 34164923
Front Immunol. 2021 Jan 08;11:573158
pubmed: 33488574
Front Microbiol. 2018 Jan 12;8:2699
pubmed: 29375539
Int J Mol Sci. 2020 May 05;21(9):
pubmed: 32380676
NPJ Biofilms Microbiomes. 2022 Oct 20;8(1):85
pubmed: 36266278
J Transl Med. 2021 Nov 29;19(1):485
pubmed: 34844611
Gut. 2019 Sep;68(9):1624-1632
pubmed: 31092590
Nat Rev Gastroenterol Hepatol. 2019 Nov;16(11):690-704
pubmed: 31554963
Sci Rep. 2019 Dec 27;9(1):20198
pubmed: 31882610
J Inflamm Res. 2022 Feb 04;15:747-759
pubmed: 35153499
Gut. 2022 Jul;71(7):1315-1325
pubmed: 34462336
Therap Adv Gastroenterol. 2016 Jul;9(4):594-605
pubmed: 27366226
Nat Rev Gastroenterol Hepatol. 2011 Nov 15;8(12):662
pubmed: 22083120
Cancer Cell Int. 2021 May 12;21(1):258
pubmed: 33980239
Cell Host Microbe. 2013 Aug 14;14(2):207-15
pubmed: 23954159
Gut. 2003 Jan;52(1):79-83
pubmed: 12477765
Cancer Sci. 2020 Mar;111(3):766-773
pubmed: 31910311
Cancer Res. 2014 Mar 1;74(5):1311-8
pubmed: 24385213
Nat Med. 2019 Jun;25(6):968-976
pubmed: 31171880
PLoS One. 2016 Mar 25;11(3):e0152126
pubmed: 27015276
EBioMedicine. 2019 Oct;48:648-655
pubmed: 31631043
World J Gastroenterol. 2017 Dec 28;23(48):8626-8650
pubmed: 29358871
Front Cell Dev Biol. 2021 Jan 12;8:603837
pubmed: 33511116
Sci Rep. 2020 Oct 1;10(1):16356
pubmed: 33004967
PLoS One. 2013 Aug 06;8(8):e70803
pubmed: 23940645
Diagnostics (Basel). 2021 Jul 30;11(8):
pubmed: 34441309
Transl Oncol. 2021 Oct;14(10):101174
pubmed: 34243011
PLoS One. 2017 Dec 7;12(12):e0189319
pubmed: 29216329
Semin Surg Oncol. 1992 Mar-Apr;8(2):89-93
pubmed: 1615269
Front Cell Infect Microbiol. 2021 Dec 17;11:744049
pubmed: 34976850
Gut Microbes. 2020;11(2):158-171
pubmed: 31595814